Ticagrelor is a P2Y12 platelet inhibitor used in patients with a history of myocardial infarction or with acute coronary syndrome (ACS) to prevent future myocardial infarction, stroke and cardiovascular death. Ticagrelor, or AZD6140, was first described in the literature in 2003.
- Mechanism
- Curator reviewed · 5 references
Ticagrelor is a P2Y12 receptor antagonist.
The P2Y12 receptor couples with Gαi2 and other Gi proteins which inhibit adenylyl cyclase. Gi mediated signalling also activates PI3K, Akt, Rap1b, and potassium channels. The downstream effects of these activities mediate hemostasis and lead to platelet aggregation.
Antagonism of the P2Y12 receptor reduces development of occlusive thromboses, which can reduce the risk of myocardial infarction and ischemic stroke.
- Primary indication
- Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction.Curator reviewed · 11 structured indications
- Formula / weight
- C23H28F2N6O4S · 522.568 g/mol (avg)
- First approval
- Canada, 2011 · United States, 2011 · European Union, 2016
- Code names
- AR-C126532XX · AZD-6140
- Brand names
Resolves to
OEKWJQXRCDYSHL-FNOIDJSQSA-NSMILESCCCSC1=NC2=C(N=NN2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)C(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=N1What you can answer from here — as of June 15, 2026
Which drugs share a target with Ticagrelor, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account